Wang Jianchao, Ding Wenshuang, Gao Limin, Yao Wenqing, Chen Min, Zhao Sha, Liu Weiping, Zhang Wenyan
1 West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Int J Surg Pathol. 2017 Apr;25(2):118-126. doi: 10.1177/1066896916665203. Epub 2016 Sep 24.
Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of diffuse large B-cell lymphoma. Thirteen cases of IVLBCL with a median age of 56 years were analyzed retrospectively. Nonspecific symptoms such as fever and hepatosplenomegaly were the most common manifestations, and the bone marrow was usually involved in 8/13 (61.5%) cases. All tumors expressed CD20, and 12/13 (92.3%) of the tumors exhibited a nongerminal center phenotype by Hans algorithm. CD5 was expressed in 3/12 (25%) of the tumors. MYC was negative in all cases, and BCL2 was positive in 10/12 (83.3%) cases. Cytogenetic analysis revealed 5 cases that did not have rearrangements in either the MYC or the BCL2 gene. No association with Epstein-Barr virus was found. Seven of 11 patients received chemotherapy. The median survival time was 6 months. Patients with hemophagocytic syndrome had poor prognoses. Our study demonstrates that IVLBCL has a poor clinical outcome with a high frequency of bone marrow involvement and that the MYC gene may not play an important role in the poor prognosis of IVLBCL.
血管内大B细胞淋巴瘤(IVLBCL)是弥漫性大B细胞淋巴瘤的一种罕见亚型。对13例IVLBCL患者进行回顾性分析,患者中位年龄为56岁。发热和肝脾肿大等非特异性症状是最常见的表现,13例中有8例(61.5%)骨髓通常受累。所有肿瘤均表达CD20,按照汉斯算法,13例中有12例(92.3%)肿瘤表现为非生发中心表型。3/12(25%)的肿瘤表达CD5。所有病例中MYC均为阴性,12例中有10例(83.3%)BCL2为阳性。细胞遗传学分析显示,5例患者的MYC或BCL2基因均未发生重排。未发现与爱泼斯坦-巴尔病毒有关联。11例患者中有7例接受了化疗。中位生存时间为6个月。噬血细胞综合征患者预后较差。我们的研究表明,IVLBCL临床结局较差,骨髓受累频率高,且MYC基因可能在IVLBCL的不良预后中不起重要作用。